CHICAGO, April 3, 2014 /PRNewswire/ -- Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the Gilead (Nasdaq:GILD-Free Report), MannKind (Nasdaq:MNKD-Free Report), Cubist (Nasdaq:CBST-Free Report), Regeneron(Nasdaq:REGN-Free Report) and Medicines Co.(Nasdaq:MDCO-Free Report).
Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1Stock of the Day pick for free.
Here are highlights from Wednesday's Analyst Blog:
Biotech Stock Roundup
Weakness in the biotech sector continued last week. The selloff, which was triggered by concerns raised by lawmakers regarding the pricing of Gilead's (Nasdaq:GILD-Free Report) hepatitis C virus (HCV) drug, Sovaldi, continued with several major companies seeing a decline in their share price. Efforts to stage a comeback were in vain with NASDAQ Biotechnology declining 7.0% and the NYSE ARCA Biotech Index declining 6.7% at the end of the week.
This week has turned out to be pretty eventful so far with a few FDA panel meetings, court rulings, and regulatory updates.
Third Time Lucky for MannKind's (Nasdaq:MNKD-Free Report)Afrezza?After a choppy start to the week when concerns regarding FDA briefing documents on Afrezza surfaced, MannKind investors had a lot to cheer about – an FDA advisory panel voted in favor of approving Afrezza for type I (13-1) and type II (14-0) diabetes. Shares were up significantly in pre-market trading.
Cubist (Nasdaq:CBST-Free Report)Drug Closer to FDA Approval: Cubist investors had a good start to the week with the company receiving a favorable recommendation from an FDA advisory panel for its experimental anti-infective drug – Sivextro (tedizolid). Shares were up 4.4%.
Regeneron (Nasdaq:REGN-Free Report)Armed with PCSK9 Data: Regeneron and partner Sanofi were not to be left behind where positive data on PCSK9 inhibitors is concerned. The companies said that their experimental PCSK9 inhibitor, alirocumab, lowered "bad" cholesterol significantly in Japanese patients.
The Medicines Co.'s (Nasdaq:MDCO-Free Report) Shares Tumble: The week so far has not been great for The Medicines Co. – shares fell 16.5% on an unfavorable trial opinion in a patent infringement lawsuit regarding Angiomax.
Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1Stock of the Day pick for free.
About Zacks Equity Research
Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.
Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.
Zacks "Profit from the Pros" e-mail newsletter provides highlights of the latest analysis from Zacks Equity Research. Subscribe to this free newsletter today.
About Zacks
Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1978. The later formation of the Zacks Rank, a proprietary stock picking system; continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter; Profit from the Pros. In short, it's your steady flow of Profitable ideas GUARANTEED to be worth your time! Register for your free subscription to Profit from the Pros.
Get the full Report on GILD - FREE
Get the full Report on MNKD - FREE
Get the full Report on CBST - FREE
Get the full Report on REGN - FREE
Get the full Report on MDCO - FREE
Follow us on Twitter: http://twitter.com/zacksresearch
Join us on Facebook: http://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts
Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.
Logo - http://photos.prnewswire.com/prnh/20101027/ZIRLOGO
SOURCE Zacks Investment Research, Inc.
Share this article